Chronic hepatitis C in elderly patients


Citar

Texto integral

Resumo

The present article discusses the epidemiology, the course and complications of chronic hepatitis C (CHC) in elderly patients. Indications and possible contraindications to antiviral therapy (AVT) in this category of patients are presented. It is noted that in elderly patients with chronic hepatitis C unsatisfactory results of AVT have been frequently reported, perhaps due to a combination of a number of adverse factors (progressive hepatic fibrosis, genotype 1 HCV infection, high viral load, presence metabolic and alcoholic steatohepatitis, low adherence to AVT due to poor tolerability of treatment, etc.). The problem of advisability of AVT in elderly patient with chronic hepatitis C adjusted for risk-benefit ratio should be resolved in each case individually, taking into account all factors (comorbidity, activity of chronic hepatitis C and stage of disease, etc.).

Bibliografia

  1. www.who.int/mediacentre/factsheets/fs164/en/
  2. Monica F, Lirussi F, Nassuato G, et al. Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea study. J Viral Hepat 1998;5:345-51.
  3. Van der Poel CL, Kuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994;344:1475-79.
  4. Sirchia G, Almini D, Bellobuono A, et al. Prevalence of hepatitis C virus antibodies in Italian blood donors. Vox Sang 1990;59:26-29.
  5. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
  6. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
  7. Мarcus EL, Dahoudi N, Tur-Kaspa R. Hepatitis C virus infection among elderly patients in a geriatric hospital. Arch Gerontol Geriatrics 1994;19:213-21.
  8. Balogun MA, Ramsay ME, Hesketh LM, et al. The prevalence of hepatitis C in England and Wales. J Infect 2002;45:219-26.
  9. Thierfelder W, Hellenbrand W, Meisel H, et al. Prevalence of markers for hepatitis A, B and C in the German population: results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001;17:429-35.
  10. Sawabe M, Arai T, Esaki Y, et al. Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases. Liver 1999;19:335-42.
  11. Okayama A, Stuver SO, Tabor E, et al. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepat 2002;9:43-51.
  12. Mazzeo C, Azzaroli F, Giovanelli S, et al. Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut, 2003;52:1030-34.
  13. Baldo V, Floreani A, Menegon T, et al. Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. Gerontology 2000;46:194-98.
  14. Maggi G, Armitano S, Brambilla L, et al. Hepatitis C infection in an Italian population not selected for risk factors. Liver 1999;19:427-31.
  15. Stroffolini T, Menchinelli M, Taliani G, et al. High prevalence of hepatitis C virus in small central Italian town: lack of evidence of parenteral exposure. Ital J Gastroenterol 1995;27:235-38.
  16. Maio G, D'Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine aminotransferase levels in the general population: a survey in a southern Italian town. J Hepatol 2000;33:116-20.
  17. Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, et al. Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand. J Infect Dis 1996;28:17-20.
  18. Dubois F, Desenclos JC, Mariotte N, et al. Hepatitis C in a French population based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997;25:1490-96.
  19. Brind AM, Watson JP, James OF, et al. Hepatitis C virus infection in the elderly. Q J M 1996;89:291-96.
  20. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-82.
  21. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008;48:1690-99.
  22. Masuko K, Mitsui T, Iwano K, et al. Infection with hepatitis GB virus C in patients on hemodialysis. N Engl J Med 1996;334:1485-90.
  23. Saxena AK, Panhotra BR. The vulnerability of middle-aged and elderly patients to hepatitis C Virus infection in a high-prevalence hospital-based hemodialysis setting. J Am Geriatr Soc 2004;52:242-46.
  24. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;6(1):35-46.
  25. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101:1260-67.
  26. Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002;99:4588-91.
  27. Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-66.
  28. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-39.
  29. Подымова С.Д., Азов А.Г. Вирусные гепатиты у пожилых пациентов. Особенности эпидемиологии, клинической картины, профилактики и лечения. Вирусные гепатиты. Достижения и перспективы. 2001. № 1. C. 3-12.
  30. Simmonds P, Mellor J, Craxi A, et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatol 1996;24:517-24.
  31. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
  32. Ohishi W, Kitamoto M, Aikata H, et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand. J Gastroenterol 2003;38:894-900.
  33. Hoshida Y, Ikeda K, Kobayashi M, et al. Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis. J Hepatol 1999;31:860-66.
  34. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007;27:186-91.
  35. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008;12:611-36.
  36. Wali M, Harrison RP, Gow PJ, et al. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-52.
  37. D'Souza R, Glynn MJ, Ushiro-Lumb I, et al. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005;3:910-17.
  38. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
  39. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
  40. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
  41. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
  42. Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36(1):226-36.
  43. Bresci G, Del Corso L, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 1993;41:857-62.
  44. Horiike N., Masumoto T., Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:246-49.
  45. Van Thiel DH, Friedlander L, Caraceni P, et al. Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci 1995;50:330-33.
  46. Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment in elderly patients with chronic hepatitis C. Infez Med 2003;11:208-12.
  47. Koyama R, Arase Y, Ikeda K, et al. Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2006;49:121-26.
  48. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004;39:1069-77.
  49. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-14.
  50. Nudo CG, Wong P, Hilzenrat N, et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can. J Gastroenterol 2006;20:589-92.
  51. Honda T, Katano Y, Urano F, et al. Efficacy of ribavirin plus interferon-alpha in patients aged > or = 60 years with chronic hepatitis C. J Gastroenterol Hepatol 2007;22:989-95.
  52. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54-63.
  53. Gupta SK, Glue P, Jacobs S, et al. Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjects. Br J Clin Pharmacol 2003;56:131-34.
  54. Martin NE, Modi MW, Reddy KR. Characterization of pegylated (40 kDa) interferon α-2a in the elderly. Hepatology 2000;32(4):755.
  55. Floreani A, Minola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc 2006;54:549-50.
  56. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007;102:1383-91.
  57. Maddrey WC, Afdhal NH, Jacobson IM, et al. HCV management today and tomorrow: tailoring therapy by genotype, viral response, and novel targets. Gastroenterol Hepatol 2007;3:4-14.
  58. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007;50:16-23.
  59. Marotta P, Feinman SV, Ghent C, et al. Final results of the canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) program. Sustained virologic response to weight-based peginterferon alfa-2b + ribavirin in a large, mixed, community and academic observational study. Hepatology 2007;46:254.
  60. Fabris P, Floreani A, Carlotto A, et al. Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2005;21:1173-78.
  61. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
  62. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999;44:874-80.
  63. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-69.
  64. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-81.
  65. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004;19:1312-27.
  66. Gish RG, Arora S, Nelson D, et al. End-of-treatment response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon α-2a. Hepatology 2004;40:519.
  67. Horikawa N, Yamazaki T, Izumi N, et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-α therapy: a prospective study. Gen Hosp Psychiatry 2003;25:34-8.
  68. www.mhlw.go.jp <http://www.mhlw.go.jp>
  69. Arias E. United States life tables, 2002. Natl Vital Stat Rep 2004;53:1-38.
  70. Mindikoglu AL, Miller RR. Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin Gastroenterol Hepatol 2009;7:128-34.
  71. Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008;25:9-18.
  72. www.gks.ru/free_doc/new_site/population/demo/demo26.htm <http://www.gks.ru/free_doc/new_site/population/demo/demo26.htm>
  73. Marcus EL, Tur-Kaspa R. Chronic hepatitis C virus infection in older adults. Clin Infect Dis 2005;41:1610-11.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2010

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies